| Literature DB >> 31085755 |
Patrick A Brown1, Matthew Wieduwilt2, Aaron Logan3, Daniel J DeAngelo4, Eunice S Wang5, Amir Fathi6, Ryan D Cassaday7, Mark Litzow8, Anjali Advani9, Patricia Aoun10, Bhavana Bhatnagar11, Michael W Boyer12, Teresa Bryan13, Patrick W Burke14, Peter F Coccia15, Steven E Coutre16, Nitin Jain17, Suzanne Kirby18, Arthur Liu19, Stephanie Massaro20, Ryan J Mattison21, Olalekan Oluwole22, Nikolaos Papadantonakis13, Jae Park23, Jeffrey E Rubnitz24, Geoffrey L Uy25, Kristina M Gregory26, Ndiya Ogba26, Bijal Shah27.
Abstract
Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.Entities:
Year: 2019 PMID： 31085755 DOI： 10.6004/jnccn.2019.0024
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908